SEC Form 4 · accession 0001144204-15-032631
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harlan Waksal
Director
Period of report
May 18, 2015
Accepted (ET)
May 20, 2015 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock OptionF1 | $0.97 | May 18, 2015 | A | 11,340 | A | May 18, 2015 | May 18, 2025 | Common Stock | 11,340 | 147,693 | D |
Explanation of responses
- F1Such options were granted to Dr. Waksal in lieu of cash compensation under the Company's independent director compensation plan.